Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

radium-223

AstraZeneca AZ

AZ’s comeback drug cediranib stumbles in phase 3 trial

Failed to improve on platinum-based chemotherapy

AstraZeneca AZ

AstraZeneca’s Imfinzi fails first-line bladder cancer test

Unable to improve overall survival in advanced metastatic bladder cancer

- PMLiVE

GSK seeks EU approval for Trelegy in adult asthma patients

If approved would open up a large market for the triple therapy

- PMLiVE

FDA accepts review to broaden GSK’s Zejula label

Seeks approval in advanced ‘all-comer’ ovarian cancer population

- PMLiVE

GSK pays $50m upfront to tap Immatics’ cell therapy platform

Deal focuses on T cell receptor therapies

Novartis day

Bayer shares dip as Novartis gets EU okay for Beovu in wet AMD

New drug due for launch in Europe in the second quarter

AstraZeneca AZ

AZ revenues rise, but it says coronavirus could hit 2020

Product sales up 12% to $23.57bn for the full-year

- PMLiVE

GSK considers more divestments to help R&D push

Turns priority to future growth drivers and R&D investment

- PMLiVE

HIV vaccine based on Sanofi/GSK components fails trial

Data suggested vaccine was no more effective than placebo

- PMLiVE

GSK and Gilead join global efforts to tackle novel coronavirus

Confirmed cases rise to over 17,000 in China

- PMLiVE

GSK licenses its tuberculosis vaccine to Gates MRI

Vaccine has demonstrated around 50% efficacy in preventing disease

- PMLiVE

AZ, Daiichi Sankyo’s Enhertu set fair for filing in gastric cancer

Improved overall survival when compared to chemotherapy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links